RU2020133847A - PHARMACEUTICAL COMPOSITIONS OF HER2 ANTIBODY CONJUGATE - Google Patents
PHARMACEUTICAL COMPOSITIONS OF HER2 ANTIBODY CONJUGATE Download PDFInfo
- Publication number
- RU2020133847A RU2020133847A RU2020133847A RU2020133847A RU2020133847A RU 2020133847 A RU2020133847 A RU 2020133847A RU 2020133847 A RU2020133847 A RU 2020133847A RU 2020133847 A RU2020133847 A RU 2020133847A RU 2020133847 A RU2020133847 A RU 2020133847A
- Authority
- RU
- Russia
- Prior art keywords
- mmol
- pharmaceutical composition
- aqueous liquid
- liquid pharmaceutical
- antibody
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims 28
- 108090001123 antibodies Proteins 0.000 title claims 4
- 102000004965 antibodies Human genes 0.000 title claims 4
- 102100016662 ERBB2 Human genes 0.000 title 1
- 101700025368 ERBB2 Proteins 0.000 title 1
- 101710037934 QRSL1 Proteins 0.000 title 1
- 239000007788 liquid Substances 0.000 claims 19
- 150000001413 amino acids Chemical class 0.000 claims 10
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 claims 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 9
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 9
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 claims 9
- 239000000611 antibody drug conjugate Substances 0.000 claims 9
- 108091008116 antibody drug conjugates Proteins 0.000 claims 9
- 239000000594 mannitol Substances 0.000 claims 9
- 235000010355 mannitol Nutrition 0.000 claims 9
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 9
- 229920000053 polysorbate 80 Polymers 0.000 claims 9
- 239000005720 sucrose Substances 0.000 claims 9
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2S)-2-amino-3-(1H-imidazol-5-yl)propanoic acid;hydron;chloride Chemical group Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 claims 8
- 235000001014 amino acid Nutrition 0.000 claims 8
- 108010045030 monoclonal antibodies Proteins 0.000 claims 8
- 102000005614 monoclonal antibodies Human genes 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 7
- 239000002904 solvent Substances 0.000 claims 7
- 235000000346 sugar Nutrition 0.000 claims 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 6
- DASWEROEPLKSEI-UIJRFTGLSA-N Monomethyl auristatin E Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)C1=CC=CC=C1 DASWEROEPLKSEI-UIJRFTGLSA-N 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 239000004475 Arginine Substances 0.000 claims 2
- 101710042656 BQ2027_MB1231C Proteins 0.000 claims 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 2
- 229960003121 arginine Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 150000008163 sugars Chemical class 0.000 claims 2
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2S)-2-[[(2R,3R)-3-methoxy-3-[(2S)-1-[(3R,4S,5S)-3-methoxy-5-methyl-4-[methyl-[(2S)-3-methyl-2-[[(2S)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 claims 1
- 229960003767 Alanine Drugs 0.000 claims 1
- 229960003589 Arginine hydrochloride Drugs 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010017758 Gastric cancer Diseases 0.000 claims 1
- 206010062878 Gastrooesophageal cancer Diseases 0.000 claims 1
- 229960002989 Glutamic Acid Drugs 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 229960002449 Glycine Drugs 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 229960002885 Histidine Drugs 0.000 claims 1
- 229940021015 I.V. solution additive Amino Acids Drugs 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical group OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N Trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 108091006028 chimera Proteins 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 201000006974 gastroesophageal cancer Diseases 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Claims (29)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910231203.4 | 2019-03-26 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2023110768A Division RU2023110768A (en) | 2019-03-26 | 2020-03-25 | PHARMACEUTICAL COMPOSITIONS OF ANTIBODY TO HER2 DRUG CONJUGATE |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2020133847A true RU2020133847A (en) | 2022-09-26 |
RU2795196C2 RU2795196C2 (en) | 2023-05-02 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA3073383C (en) | Antibody-drug conjugate preparation and lyophilization for same | |
CN112566942A (en) | Efficient methods for making antibody-drug conjugates | |
RU2766586C2 (en) | Pharmaceutical composition for treatment and/or prevention of malignant tumor | |
RU2754684C2 (en) | Binding molecules, namely antibodies capable of binding to l1cam (cd171) | |
JP6616776B2 (en) | Antibody-drug conjugates and immunotoxins | |
JP2022008618A (en) | Antibodies that specifically bind to muc1 and uses thereof | |
CA3115747A1 (en) | Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex | |
JP7470154B2 (en) | Use of anti-her2 antibody-drug conjugates in the treatment of urothelial cancer - Patent Application 20100223333 | |
CA3005294A1 (en) | Anti-5t4 antibodies and antibody-drug conjugates | |
JP7264986B2 (en) | Formulations of Anti-Her2 Antibody Drug Conjugates | |
TW202220702A (en) | Pharmaceutical composition comprising antibody drug conjugate and use thereof | |
TW201905000A (en) | Antibody-drug conjugate containing anti-GLOBO H antibody and use thereof | |
JP2020509010A5 (en) | ||
RU2020133847A (en) | PHARMACEUTICAL COMPOSITIONS OF HER2 ANTIBODY CONJUGATE | |
RU2023110768A (en) | PHARMACEUTICAL COMPOSITIONS OF ANTIBODY TO HER2 DRUG CONJUGATE | |
WO2023143365A1 (en) | Her3 antibody-drug conjugate and use thereof | |
WO2022268214A1 (en) | Pharmaceutical composition of pcsk9 inhibitor and glp-1 receptor agonist | |
EP4257603A1 (en) | Pharmaceutical composition comprising anti-connective tissue growth factor antibody | |
CN116157417A (en) | Method for producing antibody-drug conjugate | |
RU2789476C2 (en) | Production of antibody-drug conjugate and its lyophilization | |
WO2023277113A1 (en) | Humanized antibody capable of binding to heg1 protein | |
WO2023151613A1 (en) | Bispecific antigen-binding molecule and use thereof | |
KR102110182B1 (en) | Novel oxime derivative compounds and antibody-drug conjugate comprising thereof | |
TW202408589A (en) | Anti-ror1 antibodies and antibody conjugates, compositions comprising anti‑ror1 antibodies or antibody conjugates, and methods of making and using anti-ror1 antibodies and antibody conjugates | |
KR20230133294A (en) | Compounds or salts thereof, and antibodies obtained therefrom |